REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,120.00
Ask: 12,124.00
Change: 68.00 (0.56%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday preview: US jobless claims, AstraZeneca in the spotlight

Wed, 10th Feb 2021 18:52

(Sharecast News) - The economic calendar on Thursday will be exceedingly light with a reading on weekly US unemployment claims the only event that might easily move markets.



Consensus is expecting but a slight drop in the number of initial jobless claims from 779,000 for the week before to 769,000.

A speech from European Central Bank vice-president, Luis De Guindos, will also be worth monitoring.

No major economic releases are scheduled in the UK.

Further afield, rate-setters in Manila are due to meet to decide on policy.



For AstraZeneca's fourth quarter, UBS analyst Michael Leuchten has penciled sales of $7.22bn, putting him slightly ahead of the consensus which is at $7.16bn.

Core operating profits on the other hand were pegged to come in at $1.94bn (consensus: $2.02bn) for earnings per share of $1.04 (consensus: $1.09).

"Top-line momentum remains key for investors," he said, adding that he expected investors to focus their questions on the outfit's business in China, which accounts for approximately a fifth of its sales.

The analyst also broke down his sales forecasts for AstraZeneca's key treatments: Tagrisso ($1.15bn), Lynparza ($483m), Imfinzi ($532m) and Calquence ($157m).

Going forwards, Leuchten expected AstraZeneca would guide towards single-digit topline growth - excluding vaccines - and for mid-to-high teens growth in earnings per share, with the latter not including gains from the spin-out of Viela.

Thursday 11 February

INTERIMS

MJ Gleeson

INTERIM EX-DIVIDEND DATE

Hargreaves Lansdown, Henderson Smaller Companies Inv Trust, PZ Cussons, The Mission Group

QUARTERLY EX-DIVIDEND DATE

BMO Commercial Property Trust Limited, Chenavari Toro Income Fund Limited NPV, Custodian Reit , ICG Enterprise Trust, The Renewables Infrastructure Group Limited

INTERNATIONAL ECONOMIC ANNOUNCEMENTS

Continuing Claims (US) (13:30)

Initial Jobless Claims (US) (13:30)

Q4

AstraZeneca

GMS

Coral Products, Tesco

FINALS

AstraZeneca, Coca-Cola European Partners (DI), Coca-Cola HBC AG (CDI), Relx plc, Yamana Gold Inc. NPV (CDI)

SPECIAL EX-DIVIDEND DATE

Anglo Asian Mining

EGMS

Glanbia, Law Debenture Corp.

AGMS

Euromoney Institutional Investor

UK ECONOMIC ANNOUNCEMENTS

RICS Housing Market Survey (00:01)

FINAL DIVIDEND PAYMENT DATE

Hargreave Hale AIM VCT , Sage Group, Unicorn AIM VCT

FINAL EX-DIVIDEND DATE

Aberforth Smaller Companies Trust, Avon Rubber, Blackrock Income And Growth Investment Trust, Northamber
More News
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.